Top Biotech Stocks To Invest In 2014

With March Madness in full swing, we decided to stick with what we know here at The Motley Fool, trading our basketball picks in for stock picks. We formed our own bracket filled with the top Big Pharma and Big Biotech stocks in a winner take-all tournament as determined by the collective intelligence of our CAPS community.

This Final Four matchup is a heavyweight bout between Celgene�and�Johnson & Johnson. Watch and find out what J&J and embattled Rutgers University have in common and whether Celgene's style of play is enough to advance to the championship round.

Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand-new premium report on Celgene. To claim your copy today, simply click here now.

Top Biotech Stocks To Invest In 2014: France Telecom S.A.(FTE)

France Telecom provides fixed telephony and mobile telecommunications, data transmission, Internet and multimedia, and other value-added services to consumers, businesses, and telecommunications operators. It also offers personal and home communication services, business network services, international carriers and shared services, and integration and outsourcing services for communication applications. The company operates in France, Spain, Poland, the United Kingdom, and internationally. France Telecom was founded in 1990 and is based in Paris, France.

Advisors' Opinion:

• [By Chuck Carlson]

  France Telecom (NYSE:FTE): Up 1.03% to $15.68. France Telecom SA provides telecommunications services to residential, professional, and large business customers. The Company offers public fixed-line telephone, leased lines and data transmission, mobile telecommunications, cable television, Internet and wireless applications, and broadcasting services, and telecommunications equipment sales and rentals.

Top Biotech Stocks To Invest In 2014: CF Industries Holdings Inc. (CF)

CF Industries Holdings, Inc., through its subsidiary, CF Industries, Inc., manufactures and distributes nitrogen and phosphate fertilizer products, serving agricultural and industrial customers worldwide. It operates in two segments, Nitrogen and Phosphate. The Nitrogen segment principally offers ammonia, granular urea, urea ammonium nitrate solution, urea liquor, diesel exhaust fluid, and aqua ammonia. The Phosphate segment primarily offers diammonium phosphate and monoammonium phosphate. The company also owns 50% interests in the GrowHow UK Limited, a nitrogen products producer in the United Kingdom; Point Lisas Nitrogen Limited, an ammonia producer; and KEYTRADE AG, a global fertilizer trading company. CF Industries Holdings� customers include cooperatives and independent fertilizer distributors primarily in the midwestern United States. The company was founded in 1946 and is headquartered in Deerfield, Illinois.

Advisors' Opinion:

• [By Roberto Pedone]

  CF Industries (CF) is a manufacturer and distributor of nitrogen and phosphate fertilizer products in North America. This stock closed up 11.7% at $202.32 in Monday's trading session.

  Monday's Volume: 5.65 million
  
  Three-Month Average Volume: 899,814
  
  Volume % Change: 484%

  Shares of CF soared higher on Monday after billionaire Dan Loeb's Third Point Management revealed a position in the firm in its quarterly investment letter. Loeb told investors the company trades at an unwarranted discount to its peers and that it expects management to deliver a much larger dividend to shareholders.

  From a technical perspective, CF soared higher here back above both its 50-day at $184.76 and its 200-day at $198.52 with monster upside volume. This move pushed shares of CF into breakout territory, since the stock took out some key overhead resistance levels at $187.60 to $191.52 and then above $196.25 to $196.97. Shares of CF are now quickly moving within range of triggering another major breakout trade. That trade will hit if CF manages to take out some past overhead resistance at $208.17 with high volume.

  Traders should now look for long-biased trades in CF as long as it's trending above its 200-day at $198.52 or above $197 and then once it sustains a move or close above Monday's high of $202.77 to $208.17 with volume that hits near or above 899,814 shares. If that breakout triggers soon, then CF will set up to re-test or possibly take out its next major overhead resistance levels at $220 to $225.

  Keep in mind that CF is set to report earnings on Aug. 6 after the market close. Look to play that breakout before and then after earnings, once you know that the stock is reacting positively to the numbers.

• [By James K. Glassman]

   A standout in an unlikely business is CF Industries, a fertilizer producer based in Deerfield, Ill. In 2011, its free cash flow roughly doubled, to a hefty $1.8 billion, from the previous year, as it had from the preceding year as well. Lately, CF's capital expenditures have been well below its depreciation, but the company's revenues keep rising. CF's strong cash performance has, quite naturally spurred its board to boost the dividend -- from an annual rate of 40 cents per share in 2010 to a rate of $1.60 today.
  Read more at http://www.kiplinger.com/slideshow/investing/T052-S001-9-cash-rich-stocks-to-buy-now/index.html#LLDifCZJ5h4D3JBY.99 

Top 10 Dividend Companies For 2014: Biotron Ltd (BIT.AX)

Biotron Limited, a clinical stage drug development company, focuses on developing small molecule antiviral drugs targeting Hepatitis C virus (HCV), HIV, dengue, and others in Australia. The company is developing novel small molecule therapeutics that target primarily the Vpu protein of HIV and p7 protein of HCV. Its lead drug includes the BIT225, a viroporin inhibitor for the treatment of HCV and HIV infections in a Phase Ib/2a HIV trial. The company also has early stage programs target other viruses, including Dengue; and a research and development program with back-up compounds for its HIV/HCV programs. Biotron Limited is based in North Ryde, Australia.